. Enrollment is ongoing to obtain more safety data. In general, the degree of esophagitis was mild. Full assessment of survival and correlative studies will be analyzed at study completion. AB2013-2. Interim Results for Neoadjuvant Bevacizumab With Weekly
Search Results
Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™
Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction
Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa
prognosis. 2 Standard treatment for mCRC includes infusion of 5-FU plus leucovorin and oxaliplatin (FOLFOX) or infusion of 5-FU plus leucovorin and irinotecan (FOLFIRI), 3 , 4 alone or in combination with bevacizumab, 5 cetuximab, 6 or panitumumab. 7
Pre-Judging Data: Benchmarking Clinical Significance Before Study Results Are Known
Harold J. Burstein
vs. 2 years is not yet available), and ECOG 5103, which compared chemotherapy alone versus chemotherapy with bevacizumab as adjuvant treatment. These large multicenter studies have long since closed to accrual, and we are waiting for the clinical
The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value
Doreen A. Ezeife, Sunil Parimi, Ellen R. Cusano, Matthew K. Smith, Tony H. Truong, Soundouss Raissouni, Yongtao Lin, Jose G. Monzon, Haocheng Li, Vincent C. Tam, and Patricia A. Tang
. Table 4 shows the NHB score and the associated incremental cost of 4 mCRC regimens for which information was publically available. The bevacizumab/capecitabine regimen achieved the highest NHB score; however, it also had the highest incremental cost and
Developmental Therapeutics for Myelodysplastic Syndromes
Aung Naing, Lubomir Sokol, and Alan F. List
Association; June 12-15 , 2003 ; Lyon, France . 21. Gotlib J Jamieson C List A . Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS) [abstract] . Blood 2003 ; 102 : 425
Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?
Rosalyn A. Juergens and Julie R. Brahmer
without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial—E4599 (abstract) . J Clin Oncol 2005 ; 23 ( 16 suppl ): LBA4 . 5. Immerman SC
A Decade of Progress for Patients With Metastatic Colorectal Cancer: A New Decade in Which Obstacles Loom
Al B. Benson III
, subsets of patients. Within the last year, the FDA approved bevacizumab and ziv-aflibercept for treatment after first progression, and regorafenib for patients with refractory disease. Although clearly a proof of principle, our ability to appropriately
Small Cell Lung Cancer in Elderly Patients: A Review
Taofeek K. Owonikoko and Suresh Ramalingam
comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer . J Clin Oncol 2006 ; 24 : 5441 – 5447 . 85. Sandler A Gray R Perry MC . Paclitaxel-carboplatin alone or with bevacizumab
Ovarian Cancer Guidelines: Treatment Progress and Controversies
Robert J. Morgan Jr.
-increasing evidence and amend the NCCN Guidelines. The most current ongoing controversy facing the panel involves the appropriate recommendations for the addition of bevacizumab to initial treatment regimens. The committee is awaiting publication of mature data and
Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer
Gabrielle B. Rocque, Courtney P. Williams, Bradford E. Jackson, Stacey A. Ingram, Karian I. Halilova, Maria Pisu, Kelly M. Kenzik, Andres Azuero, Andres Forero, and Smita Bhatia
concordance status. The following categories of nonconcordant treatment (n=188) were identified: (1) single-agent HER2-targeted therapy (19%), (2) adjuvant regimens used in the metastatic setting (40%), (3) nonapproved bevacizumab regimens (6%), (4) therapy